References
- Akers MJ. 2002. Excipient-drug interactions in parenteral formulations. J Pharm Sci. 91:2283–2300.
- Bekers O, Uijtendaal E, Beijnen J, Underberg W. 1991. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm. 17:1503–1549.
- Brewster ME, Loftsson T. 2007. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 59:645–666.
- Chen H, Khemtong C, Yang X, Chang X, Gao J. 2011. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 16:354–360.
- Cheng Y, Paalzow L, Bondesson U, Ekblom B, Eriksson K, Eriksson S, Lindberg A, Lindstrom L. 1987. Pharmacokinetics of haloperidol in psychotic patients. Psychopharmacology (Berl). 91:410–414.
- Csernák O, Buvári-barcza Á, Samu J, Barcza L. 2005. Uncommon interactions of aliphatic dicarboxylic acids with cyclodextrins. J Incl Phenom Macrocycl Chem. 51:59–63.
- Da Conceicao Neta ER, Johanningsmeier SD, McFeeters RF. 2007. The chemistry and physiology of sour taste – a review. J Food Sci. 72:33–38.
- Demoen PJ. 1961. Properties and analysis of haloperidol and its dosage forms. J Pharm Sci. 50:350–353.
- Djedaini F, Lin SZ, Perly B, Wouessidjewe D. 1990. High-field nuclear magnetic resonance techniques for the investigation of a beta-cyclodextrin: indomethacin inclusion complex. J Pharm Sci. 79:643–646.
- Fenyvesi E, Vikmon M, Szejtli J, Redenti E, Delcanale M, Ventura P, Szejtli J. 1999. Interaction of hydroxy acids with β-cyclodextrin. J Incl Phenom Macrocycl Chem. 33:339–344.
- Higuchi T, Connors A. 1965. Phase-solubility techniques. Adv Anal Chem Instrum. 4:117–212.
- Jullian C, Morales-Montecinos J, Zapata-Torres G, Aguilera B, Rodriguez J, Arán V, Olea-Azar C. 2008. Characterization, phase-solubility, and molecular modeling of inclusion complex of 5-nitroindazole derivative with cyclodextrins. Bioorg Med Chem. 16:5078–5084.
- Kang L, Liu X, Sawant P, Ho P, Chan Y, Chan S. 2005. SMGA gels for the skin permeation of haloperidol. J Control Release. 106:88–98.
- Lee JM, Park KM, Lim SJ, Lee MK, Kim CK. 2002. Microemulsion formulation of clonixic acid: solubility enhancement and pain reduction. J Pharm Pharmacol. 54:43–49.
- Li S, Wong S, Sethia S, Almoazen H, Joshi YM, Serajuddin ATM. 2005. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm Res. 22:628–635.
- Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 85:1017–1025.
- Loftsson T, Hreinsdottir D, Masson M. 2005. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm. 302:18–29.
- Loftsson T, Hreinsdottir D, Masson M. 2007. The complexation efficiency. J Incl Phenom Macrocycl Chem. 57:545–552.
- Munoz de la Pena A, Ndou TT, Zung JB, Greene KL, Live DH, Warner IM. 1991. Alcohol size as a factor in the ternary complexes formed with pyrene and β-cyclodextrin. J Am Chem Soc. 113:1572–1577.
- Olesen OV, Linnet K. 1997. Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B Biomed Sci Appl. 698:209–216.
- Panaggio A. 1983. High pressure liquid chromatographic determination of haloperidol stability. Drug Dev Ind Pharm. 9:485–492.
- Pascal B, Maud G, Georgew D, Adelin A, Valery B, Bruno P, Didier C, Geraldine P, Luc D, Brigitte E. 2005. The effect of cyclodextrins on the aqueous solubility of a new MMP inhibitor: phase solubility, 1H-NMR spectroscopy and molecular modeling studies, preparation and stability study of nebulizable solutions. J Pharm Pharm Sci. 8:164–175.
- Patil JS, Kadam DV, Marapur SC, Kamalapur MV. 2006. Inclusion complex system; a novel technique to improve the solubility and bioavailability of poorly soluble drugs: a review. Int J Pharm Sci Rev Res. 2:29–34.
- Rakkaew P, Suksiriworapong J, Chantasart D. 2013. The influence of hydroxycarboxylic acids on the solubilization of haloperidol. Proceedings of the Burapha University International Conference 2013; 4–5 July 2013.
- Singh S, Parikh T, Sandhu HK, Shah NH, Malick AW, Singal D, Serajuddin AT. 2013. Supersolubilization and amorphization of a model basic drug, haloperidol, by interaction with weak acids. Pharm Res. 30:1561–1573.
- Szente L, Szejtli J. 2004. Cyclodextrins as food ingredients. Trends Food Sci Technol. 15:137–142.
- Tablet C, Matei I, Hillebrand M. 2012. The determination of the stoichiometry of cyclodextrin inclusion complexes by spectral methods: possibilities and limitations. In: Innocenti A, editor. Stoichiometry and research – the importance of quantity in biomedicine. Rijeka, Croatia: InTech. p. 47–76.
- Thompson DO. 1997. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst. 14:1–104.
- Uekema K, Irie T. 2004. New perspectives in cyclodextrin pharmaceutical applications cyclodextrins derivatives as new drugs carriers. Int J Pharm. 271:155–165.